Imviva Biotech Receives FDA Investigational New Drug Approval for CTA313, a Dual-Targeted CD19/BCMA Allogeneic CAR-T Cell Therapy for Autoimmune Diseases

FDA Clears Imviva Biotech's IND for CTA313 in Autoimmune Diseases

Imviva Biotech announced that the U.S. FDA has cleared its Investigational New Drug (IND) application for CTA313, a dual-targeting CD19/BCMA allogeneic CAR-T cell therapy. This approval enables a Phase 1b basket study in the United States for patients with B-cell-mediated autoimmune diseases, including systemic lupus erythematosus, progressive multiple sclerosis, and autoimmune encephalitis. This marks Imviva's strategic expansion into autoimmune therapeutics, leveraging its proprietary ANSWER™ platform technology to provide an off-the-shelf treatment option.

• CTA313 is an investigational dual-targeting CD19/BCMA allogeneic CAR-T cell therapy derived from healthy donors. It incorporates Imviva's proprietary ANSWER™ inhibitory ligands and genetic edits designed to enhance resistance to host immune rejection and enable therapeutic durability, offering an off-the-shelf solution.
• The FDA-cleared Phase 1b basket design will evaluate the safety, efficacy, and cellular pharmacokinetics of CTA313 across multiple B-cell-mediated autoimmune conditions. This innovative design allows for efficient evaluation across systemic lupus erythematosus, progressive multiple sclerosis, and autoimmune encephalitis, with flexibility to advance promising signals.
• The allogeneic, off-the-shelf approach of CTA313 means the therapy can be manufactured in advance and made readily available, potentially allowing eligible patients to receive treatment more quickly without the delays associated with autologous therapies, and eliminating the need for apheresis.

Addressing Unmet Needs in Systemic Lupus Erythematosus

Current systemic lupus erythematosus treatment approaches face significant challenges that limit therapeutic outcomes and patient quality of life. The complexity of SLE pathogenesis, combined with the broad-spectrum nature of available therapies, creates substantial barriers to optimal disease management. Despite therapeutic advances over recent decades, treatment remains problematic due to the balance required between controlling disease activity and preventing unacceptable treatment-related toxicities.

• Non-specific immunosuppression with significant toxicity - Current therapies rely heavily on broad-spectrum immunosuppressive agents including corticosteroids and cytotoxic drugs that cause serious side effects, with immunosuppressive treatments requiring careful tailoring to disease severity due to their considerable adverse effects

• Incomplete disease understanding - The etiology and pathogenesis of SLE and lupus nephritis remain incompletely understood, with the inciting antigen still unknown, limiting the development of targeted therapeutic approaches

• Lack of curative therapy - Although many drugs can manage the disease, curative therapy remains elusive, with current treatment regimens carrying substantial side effects and 10% of patients still progressing toward end-stage kidney disease with elevated mortality rates

• Limited therapeutic options - SLE represents an archetypical and refractory autoimmune disorder with limited therapeutic options and suboptimal outcomes, making the development of more effective approaches with minimal side effects particularly challenging due to disease complexity

• Unresolved treatment optimization issues - Key questions remain regarding which patients would benefit most from novel agents or combined drug regimens, whether new drugs should serve as alternatives to current remission-induction regimens rather than add-on therapies, and how to decrease adverse effects while maintaining efficacy

Dual-Targeting Allogeneic CAR-T: A Strategic Leap into Autoimmunity

The recent IND clearance for Imviva Biotech's CTA313 marks a significant inflection point in the pursuit of transformative therapies for autoimmune diseases. This dual-targeting allogeneic CAR-T cell therapy, aimed at CD19 and BCMA, is poised to enter clinical trials for systemic lupus erythematosus, progressive multiple sclerosis, and autoimmune encephalitis – conditions where autoreactive B cells and long-lived plasma cells are recognized as key disease drivers.

The rationale behind targeting both CD19 (on B cells) and BCMA (on plasma cells) is compelling. While B-cell depletion has proven effective in various autoimmune conditions, long-lived plasma cells can persist and continue to produce pathogenic autoantibodies, contributing to disease refractory nature. By simultaneously addressing both populations, CTA313 aims to achieve a more profound and sustained immune reset, potentially offering a deeper and more durable remission than current therapies. Early phase trials in refractory SLE with dual CD19/BCMA CAR-T have shown promising safety and clinical efficacy, supporting this innovative approach.

Furthermore, CTA313's allogeneic, 'off-the-shelf' nature is a critical differentiator. Unlike autologous CAR-T therapies, which require individualized cell collection and manufacturing, an allogeneic product could significantly streamline the treatment process, reducing manufacturing time, cost, and logistical hurdles. This enhanced accessibility could be a game-changer for patients with rapidly progressing or severe autoimmune diseases.

However, the journey is not without its challenges. While CAR-T therapies have revolutionized oncology, they are associated with known toxicities such as cytokine release syndrome and neurotoxicity, which will require careful management. The long-term persistence of CAR T-cells and the durability of remission also remain key questions, as relapse due to antigen escape or insufficient CAR T-cell activity has been observed. Additionally, the potential for immune escape in immune-privileged sites, where CAR T-cells may not effectively penetrate, warrants consideration for comprehensive disease control. Despite these risks, the strategic implications are clear: Imviva is positioning itself at the forefront of a new therapeutic paradigm, aiming to deliver potentially curative, accessible cellular therapies for debilitating autoimmune conditions.